J1600 Gold sodium thiomaleate inj

Injection, gold sodium thiomalate, up to 50 mg

Medically Unlikely Edits (effective October 1, 2026)

Medicare pricing for J1600

Physician Fee Schedule (CY 2026, RVU26D)

Status E: excluded from the PFS by regulation.

Payer policies and prior authorization for J1600

Payer coverage policies that name J1600

J1600 appears in 5 coverage policies from Aetna.

PayerPolicyRole in policyReviewedDocument
AetnaAbatacept (Orencia) (0720)
Rinvoq, Xeljanz, Otezla, Ruxolitinib, Hydroxychloroquine, Sulfasalazine		listed, no stanceJul 1, 2026payer document
AetnaAdalimumab (0655)
Anakinra (Kineret), Rinvoq, Otezla and Xeljanz, Clindamycin, Metronidazole, Rifampicin, Sulfasalazine, Leflunomide -		listed, no stanceJul 13, 2026payer document
AetnaGolimumab (Simponi and Simponi Aria) (0790)listed, no stanceJul 31, 2026payer document
AetnaInfliximab (0341)listed, no stanceOct 5, 2026payer document
AetnaInjectable Medications (0020)listed, no stance (range J0278-J2543)Mar 5, 2026payer document

Medicaid fee-for-service

  • KS: $28.45 (default), effective Apr 1, 2021
  • KY: $0.00 (asc), effective Jan 1, 2026
  • OH: $13.50 (provider_administered_drugs), effective Sep 1, 2013
  • VA: $30.15 (medical), effective Jul 1, 2013
  • VT: $0.00 (outpatient_hospital_opps), effective Feb 1, 2026
  • WA: $22.79 (professional_administered_drugs), effective Jul 1, 2026
  • WY: $0.00 (outpatient_hospital_apc, Children's Hospitals), effective Apr 1, 2026

From payers' published prior-auth lists, coverage policies and state Medicaid fee schedules, updated Oct 16, 2026. The role is what the policy's own code table or text says about the code. Not a guarantee of coverage or payment; verify with the payer. CPT® is a registered trademark of the American Medical Association.